CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of infectious diseases
3.4.1.2. Increase in consumption of oral antibiotics
3.4.1.3. Rise in investments in R&D activities
3.4.2. Restraints
3.4.2.1. Development of antibiotic resistance
3.4.2.2. Time consuming approvals
3.4.3. Opportunities
3.4.3.1. Discovery of advanced therapies to treat antibiotic- resistance.
CHAPTER 4: ORAL ANTIBIOTICS MARKET, BY CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Beta Lactam and Beta Lactamase Inhibitors
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Beta Lactam and Beta Lactamase Inhibitors Oral Antibiotics Market by Type
4.2.4.1. Penicillin Oral Antibiotics Market by Spectrum of Activity
4.3. Quinolone
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Macrolide
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY
5.1. Overview
5.1.1. Market size and forecast
5.2. Broad-spectrum Antibiotic
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Mid/Narrow-spectrum antibiotic
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: ORAL ANTIBIOTICS MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Community-acquired respiratory tract infections (CARTIs)
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.2.4. Community-acquired respiratory tract infections (CARTIs) Oral Antibiotics Market by Type
6.3. Urinary tract infections (UTIs)
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Dental
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN
7.1. Overview
7.1.1. Market size and forecast
7.2. Natural
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Semisynthetic
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Synthetic
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: ORAL ANTIBIOTICS MARKET, BY DRUG TYPE
8.1. Overview
8.1.1. Market size and forecast
8.2. Branded
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by region
8.2.3. Market share analysis by country
8.3. Generic
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by region
8.3.3. Market share analysis by country
CHAPTER 9: ORAL ANTIBIOTICS MARKET, BY REGION
9.1. Overview
9.1.1. Market size and forecast By Region
9.2. North America
9.2.1. Key market trends, growth factors and opportunities
9.2.2. Market size and forecast, by Class
9.2.3. Market size and forecast, by Spectrum of Activity
9.2.4. Market size and forecast, by Application
9.2.5. Market size and forecast, by Drug Origin
9.2.6. Market size and forecast, by Drug Type
9.2.7. Market size and forecast, by country
9.2.7.1. U.S.
9.2.7.1.1. Market size and forecast, by Class
9.2.7.1.2. Market size and forecast, by Spectrum of Activity
9.2.7.1.3. Market size and forecast, by Application
9.2.7.1.4. Market size and forecast, by Drug Origin
9.2.7.1.5. Market size and forecast, by Drug Type
9.2.7.2. Canada
9.2.7.2.1. Market size and forecast, by Class
9.2.7.2.2. Market size and forecast, by Spectrum of Activity
9.2.7.2.3. Market size and forecast, by Application
9.2.7.2.4. Market size and forecast, by Drug Origin
9.2.7.2.5. Market size and forecast, by Drug Type
9.2.7.3. Mexico
9.2.7.3.1. Market size and forecast, by Class
9.2.7.3.2. Market size and forecast, by Spectrum of Activity
9.2.7.3.3. Market size and forecast, by Application
9.2.7.3.4. Market size and forecast, by Drug Origin
9.2.7.3.5. Market size and forecast, by Drug Type
9.3. Europe
9.3.1. Key market trends, growth factors and opportunities
9.3.2. Market size and forecast, by Class
9.3.3. Market size and forecast, by Spectrum of Activity
9.3.4. Market size and forecast, by Application
9.3.5. Market size and forecast, by Drug Origin
9.3.6. Market size and forecast, by Drug Type
9.3.7. Market size and forecast, by country
9.3.7.1. Germany
9.3.7.1.1. Market size and forecast, by Class
9.3.7.1.2. Market size and forecast, by Spectrum of Activity
9.3.7.1.3. Market size and forecast, by Application
9.3.7.1.4. Market size and forecast, by Drug Origin
9.3.7.1.5. Market size and forecast, by Drug Type
9.3.7.2. France
9.3.7.2.1. Market size and forecast, by Class
9.3.7.2.2. Market size and forecast, by Spectrum of Activity
9.3.7.2.3. Market size and forecast, by Application
9.3.7.2.4. Market size and forecast, by Drug Origin
9.3.7.2.5. Market size and forecast, by Drug Type
9.3.7.3. UK
9.3.7.3.1. Market size and forecast, by Class
9.3.7.3.2. Market size and forecast, by Spectrum of Activity
9.3.7.3.3. Market size and forecast, by Application
9.3.7.3.4. Market size and forecast, by Drug Origin
9.3.7.3.5. Market size and forecast, by Drug Type
9.3.7.4. Italy
9.3.7.4.1. Market size and forecast, by Class
9.3.7.4.2. Market size and forecast, by Spectrum of Activity
9.3.7.4.3. Market size and forecast, by Application
9.3.7.4.4. Market size and forecast, by Drug Origin
9.3.7.4.5. Market size and forecast, by Drug Type
9.3.7.5. Spain
9.3.7.5.1. Market size and forecast, by Class
9.3.7.5.2. Market size and forecast, by Spectrum of Activity
9.3.7.5.3. Market size and forecast, by Application
9.3.7.5.4. Market size and forecast, by Drug Origin
9.3.7.5.5. Market size and forecast, by Drug Type
9.3.7.6. Rest of Europe
9.3.7.6.1. Market size and forecast, by Class
9.3.7.6.2. Market size and forecast, by Spectrum of Activity
9.3.7.6.3. Market size and forecast, by Application
9.3.7.6.4. Market size and forecast, by Drug Origin
9.3.7.6.5. Market size and forecast, by Drug Type
9.4. Asia-Pacific
9.4.1. Key market trends, growth factors and opportunities
9.4.2. Market size and forecast, by Class
9.4.3. Market size and forecast, by Spectrum of Activity
9.4.4. Market size and forecast, by Application
9.4.5. Market size and forecast, by Drug Origin
9.4.6. Market size and forecast, by Drug Type
9.4.7. Market size and forecast, by country
9.4.7.1. Japan
9.4.7.1.1. Market size and forecast, by Class
9.4.7.1.2. Market size and forecast, by Spectrum of Activity
9.4.7.1.3. Market size and forecast, by Application
9.4.7.1.4. Market size and forecast, by Drug Origin
9.4.7.1.5. Market size and forecast, by Drug Type
9.4.7.2. China
9.4.7.2.1. Market size and forecast, by Class
9.4.7.2.2. Market size and forecast, by Spectrum of Activity
9.4.7.2.3. Market size and forecast, by Application
9.4.7.2.4. Market size and forecast, by Drug Origin
9.4.7.2.5. Market size and forecast, by Drug Type
9.4.7.3. India
9.4.7.3.1. Market size and forecast, by Class
9.4.7.3.2. Market size and forecast, by Spectrum of Activity
9.4.7.3.3. Market size and forecast, by Application
9.4.7.3.4. Market size and forecast, by Drug Origin
9.4.7.3.5. Market size and forecast, by Drug Type
9.4.7.4. Australia
9.4.7.4.1. Market size and forecast, by Class
9.4.7.4.2. Market size and forecast, by Spectrum of Activity
9.4.7.4.3. Market size and forecast, by Application
9.4.7.4.4. Market size and forecast, by Drug Origin
9.4.7.4.5. Market size and forecast, by Drug Type
9.4.7.5. South Korea
9.4.7.5.1. Market size and forecast, by Class
9.4.7.5.2. Market size and forecast, by Spectrum of Activity
9.4.7.5.3. Market size and forecast, by Application
9.4.7.5.4. Market size and forecast, by Drug Origin
9.4.7.5.5. Market size and forecast, by Drug Type
9.4.7.6. Rest of Asia-Pacific
9.4.7.6.1. Market size and forecast, by Class
9.4.7.6.2. Market size and forecast, by Spectrum of Activity
9.4.7.6.3. Market size and forecast, by Application
9.4.7.6.4. Market size and forecast, by Drug Origin
9.4.7.6.5. Market size and forecast, by Drug Type
9.5. LAMEA
9.5.1. Key market trends, growth factors and opportunities
9.5.2. Market size and forecast, by Class
9.5.3. Market size and forecast, by Spectrum of Activity
9.5.4. Market size and forecast, by Application
9.5.5. Market size and forecast, by Drug Origin
9.5.6. Market size and forecast, by Drug Type
9.5.7. Market size and forecast, by country
9.5.7.1. Brazil
9.5.7.1.1. Market size and forecast, by Class
9.5.7.1.2. Market size and forecast, by Spectrum of Activity
9.5.7.1.3. Market size and forecast, by Application
9.5.7.1.4. Market size and forecast, by Drug Origin
9.5.7.1.5. Market size and forecast, by Drug Type
9.5.7.2. Saudi Arabia
9.5.7.2.1. Market size and forecast, by Class
9.5.7.2.2. Market size and forecast, by Spectrum of Activity
9.5.7.2.3. Market size and forecast, by Application
9.5.7.2.4. Market size and forecast, by Drug Origin
9.5.7.2.5. Market size and forecast, by Drug Type
9.5.7.3. South Africa
9.5.7.3.1. Market size and forecast, by Class
9.5.7.3.2. Market size and forecast, by Spectrum of Activity
9.5.7.3.3. Market size and forecast, by Application
9.5.7.3.4. Market size and forecast, by Drug Origin
9.5.7.3.5. Market size and forecast, by Drug Type
9.5.7.4. Rest of LAMEA
9.5.7.4.1. Market size and forecast, by Class
9.5.7.4.2. Market size and forecast, by Spectrum of Activity
9.5.7.4.3. Market size and forecast, by Application
9.5.7.4.4. Market size and forecast, by Drug Origin
9.5.7.4.5. Market size and forecast, by Drug Type
CHAPTER 10: COMPETITIVE LANDSCAPE
10.1. Introduction
10.2. Top winning strategies
10.3. Product mapping of top 10 player
10.4. Competitive dashboard
10.5. Competitive heatmap
10.6. Top player positioning, 2022
CHAPTER 11: COMPANY PROFILES
11.1. Abbott Laboratories
11.1.1. Company overview
11.1.2. Key executives
11.1.3. Company snapshot
11.1.4. Operating business segments
11.1.5. Product portfolio
11.1.6. Business performance
11.2. Alkem Laboratories Ltd.
11.2.1. Company overview
11.2.2. Key executives
11.2.3. Company snapshot
11.2.4. Operating business segments
11.2.5. Product portfolio
11.2.6. Business performance
11.3. Novartis AG
11.3.1. Company overview
11.3.2. Key executives
11.3.3. Company snapshot
11.3.4. Operating business segments
11.3.5. Product portfolio
11.3.6. Business performance
11.3.7. Key strategic moves and developments
11.4. Pfizer Inc.
11.4.1. Company overview
11.4.2. Key executives
11.4.3. Company snapshot
11.4.4. Operating business segments
11.4.5. Product portfolio
11.4.6. Business performance
11.5. Lupin
11.5.1. Company overview
11.5.2. Key executives
11.5.3. Company snapshot
11.5.4. Operating business segments
11.5.5. Product portfolio
11.5.6. Business performance
11.6. Teva Pharmaceutical Industries Limited
11.6.1. Company overview
11.6.2. Key executives
11.6.3. Company snapshot
11.6.4. Operating business segments
11.6.5. Product portfolio
11.6.6. Business performance
11.6.7. Key strategic moves and developments
11.7. Cipla Ltd
11.7.1. Company overview
11.7.2. Key executives
11.7.3. Company snapshot
11.7.4. Operating business segments
11.7.5. Product portfolio
11.7.6. Business performance
11.8. Bayer AG
11.8.1. Company overview
11.8.2. Key executives
11.8.3. Company snapshot
11.8.4. Operating business segments
11.8.5. Product portfolio
11.8.6. Business performance
11.9. F. Hoffmann-La Roche Ltd.
11.9.1. Company overview
11.9.2. Key executives
11.9.3. Company snapshot
11.9.4. Operating business segments
11.9.5. Product portfolio
11.9.6. Business performance
11.9.7. Key strategic moves and developments
11.10. SUN PHARMACEUTICAL INDUSTRIES LIMITED
11.10.1. Company overview
11.10.2. Key executives
11.10.3. Company snapshot
11.10.4. Operating business segments
11.10.5. Product portfolio
11.10.6. Business performance
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/